Celebrating 5 years from initial FDA approval

FDA approved since 2017 for adults, 2019 for teens (aged 12-17 years), 2020 for children (aged 6-11 years), and 2022 for young children (aged 6 months-5 years) with uncontrolled moderate-to-severe atopic dermatitis.

CHEERS TO 5 YEARS

Since 2017, DUPIXENT has been prescribed to thousands of adult patients (18+ years) since first approved to treat uncontrolled moderate-to-severe atopic dermatitis. a,b

FDA approved since 2017 for adults, 2019 for teens (aged 12-17 years), 2020 for children (aged 6-11 years), and 2022 for young children (aged 6 months-5 years) with uncontrolled moderate-to-severe atopic dermatitis.

a IQVIA National Source of Business (NSOB) data as of [April 2022].

b New adult patients with uncontrolled moderate-to-severe atopic dermatitis.

DUP.22.06.0381

STAY AHEAD OF ECZEMA
WITH DUPIXENT

DUPIXENT is a breakthrough treatment for uncontrolled moderate-to-severe eczema. When topical prescriptions aren’t enough, and your symptoms and flare-ups keep coming back, it may be time for a different kind of treatment.

DUPIXENT helps you stay ahead of symptoms—continuously treating eczema between flare-ups.


See how it works

DUPIXENT is a biologic that helps block a key source of inflammation inside the body that can cause eczema.

DUPIXENT is not a steroid or immunosuppressant; it is a prescription biologic medicine given under the skin (subcutaneous injection).

A BREAKTHROUGH ECZEMA TREATMENT

DUPIXENT was studied in adults and children 6 months of age and older.
See the clinical results by choosing adults (18+ years), teens (12-17 years), children (6-11 years), or young children (6 months-5 years).

FOR ADULTS
(18+ YEARS)

DUPIXENT was studied in 3 clinical trials with more than 2,100 adults with moderate-to-severe eczema not well controlled with topical prescription treatments. It was first approved by the FDA for this patient population on March 28, 2017.

View Results in
Adults

See before and after pictures

Cristal,
Real patient. Individual results may vary.

FOR TEENS
(12-17 YEARS)

DUPIXENT was studied in a 16-week clinical trial with 251 patients ages 12-17 years with moderate-to-severe eczema not well controlled with topical prescription treatments. It was approved by the FDA for this patient population on March 11, 2019.

View Results in
Teens

See before and after pictures

Tyler,
Real patient. Individual results may vary.

FOR CHILDREN
(6-11 YEARS)

DUPIXENT was studied in a 16-week clinical trial with 367 patients ages 6-11 years with severe eczema not well controlled with topical prescription treatments. It was approved by the FDA for the moderate-to-severe patient population on May 26, 2020.

View Results in
Children

See before and after pictures

Harper,
Real patient. Individual results may vary.

FOR YOUNG CHILDREN
(6 MONTHS-5 YEARS)

DUPIXENT was studied in a 16-week clinical trial with 162 patients ages 6 months to 5 years with moderate-to-severe eczema not well controlled with topical prescription treatments. It was approved by the FDA for the moderate-to-severe patient population on June 7, 2022.

View Results in young
children

See before and after pictures

Not an actual patient.
Individual results may vary.

Sean, real patient.
Individual results may vary.

TAKE YOUR SHOT AGAINST ECZEMA

It’s time to get ahead of your symptoms, so help put uncontrolled moderate-to-severe eczema in its place with DUPIXENT. Be proactive and take control with one dose every 2 or 4 weeks based on age and weight (after initial loading dose of 2 injections) for adults and children 6 years and older. For children aged 6 months to 5 years, one dose every 4 weeks based on weight, with no initial loading dose recommended.

LEARN ABOUT DUPIXENT

Your doctor will tell you how much DUPIXENT to inject and how often to inject it, following proper training. DUPIXENT is an injection given under the skin (subcutaneous injection). It can be given by a doctor in the office or a caregiver at home:

  • in children younger than 12 years, DUPIXENT should be given by a caregiver
  • in children 12 years of age and older, DUPIXENT should be given by or under the supervision of an adult

DUPIXENT MyWay® COPAY CARD

The DUPIXENT MyWay Copay Card may help eligible patients reduce the out-of-pocket cost of DUPIXENT. If you’re eligible, you can sign up and your card will be sent via email. Terms & Restrictions Apply.

See Copay Details

DUPIXENT MyWay also offers Nurse Educator support, supplemental
injection training online or in person, and more.

See more information

REAL PATIENT EXPERIENCES

Everyone has a story to tell. Hear from DUPIXENT
ambassadors as they share their messages and
lessons they’ve learned.

HEAR THEIR STORIES

Kiara,
Real patient. Individual results may vary.

Find a Specialist Who
Treats Eczema

Use this Healthgrades™ tool to easily find nearby
specialists with experience in treating children, teens,
and adults with uncontrolled moderate-to-severe
eczema (atopic dermatitis).